WATERTOWN, Mass. , May 17, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, enhance gene therapies and mitigate unwanted immune responses to
– Phase 1 trial of SEL-302 remains on track to initiate in the second half of 2022 – – DISSOLVE I & II studies on track for completion in Q4 2022 with joint topline readout in Q1 2023 – – Completed underwritten offering, raising approximately $38.7 million in gross proceeds, extending runway into
Data to be featured in two oral presentations and four poster presentations WATERTOWN, Mass. , May 02, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies for autoimmune
WATERTOWN, Mass. , April 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that it plans to host a
WATERTOWN, Mass. , April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company focused on developing tolerogenic therapies to mitigate unwanted immune responses, today announced that it has agreed to sell 27,428,572 shares of its
WATERTOWN, Mass. , April 04, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR ® platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s
– U.S. Food and Drug Administration (“FDA”) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (“MMA”)- -Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune
WATERTOWN, Mass. , Feb. 09, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management
Leveraging Ginkgo’s high throughput screening and cell engineering capabilities and Selecta’s ImmTOR platform to advance gene therapy delivery with the goal of improved transduction, enhanced tissue tropism and reduced immunogenicity WATERTOWN, Mass. and BOSTON , Jan.
